News from jazz pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

22 Jan, 2020, 13:00 GMT Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on...


22 Jan, 2020, 07:30 GMT PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements...


20 Jan, 2020, 15:41 GMT Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Sunosi® (solriamfetol) to improve wakefulness and...


06 Jan, 2020, 21:05 GMT Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan ...


30 Dec, 2019, 13:00 GMT Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, ...


19 Dec, 2019, 13:00 GMT PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.

- Jazz to pay an upfront payment of $200 million to PharmaMar - Opportunity for Jazz to expand its oncology portfolio with lurbinectedin, a late...


15 Nov, 2019, 11:45 GMT Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...


14 Nov, 2019, 21:05 GMT Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at three upcoming investor...


07 Nov, 2019, 13:00 GMT Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 15 abstracts sponsored by Jazz Pharmaceuticals, including one oral presentation, one...


05 Nov, 2019, 21:05 GMT Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results

Total Revenues Increased 15% to $538 Million GAAP Diluted EPS of $1.78; Adjusted Diluted EPS of $4.10 2019 Total Revenues Guidance Increased to...


22 Oct, 2019, 21:05 BST Jazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 third quarter financial results on Tuesday, November 5, 2019,...


10 Oct, 2019, 21:15 BST Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating...


30 Sep, 2019, 13:30 BST Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and ...


26 Sep, 2019, 01:00 BST Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the...


18 Sep, 2019, 21:05 BST Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, September 25, 2019 at 9:00 p.m. EDT/2:00 a....


27 Aug, 2019, 21:05 BST Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


12 Aug, 2019, 21:01 BST Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.

Transaction Adds Worldwide Rights to CX-8998, a Modulator of T-type Calcium Channels, for the Potential Treatment of Essential Tremor Strong...


06 Aug, 2019, 21:01 BST Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy...


23 Jul, 2019, 21:05 BST Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019,...


10 Jul, 2019, 07:00 BST Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a definitive agreement under which Jazz has acquired Redx...


25 Jun, 2019, 21:05 BST Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 2, 2019 at 4:30 p.m. EDT/9:30 p.m. IST...


17 Jun, 2019, 13:00 BST Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as...


03 Jun, 2019, 13:00 BST Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Robert Iannone, M.D., M.S.C.E., as executive vice president, research and...


16 May, 2019, 21:30 BST Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present data from across its hematology/oncology portfolio and pipeline at the...